×
About 5,813 results

ALLMedicine™ Plaque Psoriasis Center

Research & Reviews  1,512 results

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
https://doi.org/10.1002/14651858.CD011535.pub5
The Cochrane Database of Systematic Reviews; Sbidian E, Chaimani A et. al.

May 24th, 2022 - Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of di...

Transforming the treatment of psoriasis to the 21st century: Detecting subclinical ther...
https://doi.org/10.1002/lsm.23551
Lasers in Surgery and Medicine; Felice S, Bressler MY et. al.

May 23rd, 2022 - Optical coherence tomography (OCT) is a noninvasive imaging device that scans the skin up to 2 mm in depth. OCT can capture real-time epidermal thickness (ET) measurements and detect subclinical changes in inflammatory skin diseases like eczema an...

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
https://clinicaltrials.gov/ct2/show/NCT04435600

May 20th, 2022 - Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There is an unmet medical need for effective treatment in pediatric patients and this study is being do...

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT04718896

May 20th, 2022 - The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT05268016

May 20th, 2022 - The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults.

see more →

Guidelines  1 results

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway.
https://doi.org/10.1159/000512930
Dermatology (Basel, Switzerland); Maul JT, Anzengruber F et. al.

Jan 7th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

see more →

Drugs  130 results see all →

Clinicaltrials.gov  223 results

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT04718896

May 20th, 2022 - The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
https://clinicaltrials.gov/ct2/show/NCT04435600

May 20th, 2022 - Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There is an unmet medical need for effective treatment in pediatric patients and this study is being do...

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT05268016

May 20th, 2022 - The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults.

Impact of Non-surgical Periodontal Therapy in the Management of Plaque Psoriasis.
https://clinicaltrials.gov/ct2/show/NCT05311501

May 18th, 2022 - Both periodontitis and plaque psoriasis are non communicable chronic inflammatory diseases. They share genetic polymorphysms (IL-1, IL-6 e TNFalfa) and risk factors (smoking, diabetes, obesity), as well as a great resemblance in terms of pathophys...

A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting ...
https://clinicaltrials.gov/ct2/show/NCT04894890

May 17th, 2022 - All patients will be followed up for 52 weeks no matter they adhere to secukinumab or they have shifted to other treatment plans. Data will be collected in conjunction with routine care visits, most likely happen at week 0, 4, 12, 16, 24, 36, 52. ...

see more →

News  459 results

Study Links Air Pollution to Psoriasis Flares
https://www.medscape.com/viewarticle/969146

Feb 24th, 2022 - Exposure to air pollution — even short term — may play a role in triggering psoriasis flares, according to new research from Italy, which found a significant association between exposure to higher levels of air pollution prior to patients presenti...

How Clinical Pharmacists Can Help Extend the Reach of Psoriatic Arthritis Care
https://www.medscape.com/viewarticle/959149

Feb 22nd, 2022 - This transcript has been edited for clarity. Elaine Husni, MD, MPH: Hi. Welcome, everyone, to Medscape InDiscussion, episode four. We're really excited to talk about extending the reach of psoriatic arthritis patient care with clinical pharmacists...

FDA Approvals, Highlights, and Summaries: Dermatology
https://www.medscape.com/viewarticle/967603

Feb 17th, 2022 - Adbry (tralokinumab) Tralokinumab is an interleukin-13 (IL-13) inhibitor that blocks IL-13–induced responses (eg, release of proinflammatory cytokines, chemokines, IgE). It is indicated for moderate-to-severe atopic dermatitis in adults who are no...

Guselkumab Cuts Disease Activity in Crohn's
https://www.medpagetoday.com/gastroenterology/inflammatoryboweldisease/97073

Feb 8th, 2022 - The selective p19 interleukin (IL)-23 blocker guselkumab (Tremfya) was safe and reduced disease activity in adults with moderate to severe Crohn's disease who had an inadequate response to prior therapies, a randomized phase II trial found. For th...

More Frequent Secukinumab Dosing Found to Benefit Overweight Patients With Psoriasis
https://www.medscape.com/viewarticle/967306

Jan 26th, 2022 - Over the period of 1 year, secukinumab 300 mg every 2 weeks demonstrated superior efficacy compared with secukinumab 300 mg every 4 weeks in overweight patients with moderate to severe plaque psoriasis, results from a multicenter, double-blind, pa...

see more →